Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.6.1.2 (
alanine aminotransferase
)
26,722
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Acute intermittent porphyria
is an autosomal dominant inherited disorder resulting from a deficiency of porphobilinogen deaminase activity, the third enzyme in the heme biosynthesis pathway. This disease is uncommon, although the prevalence is higher in asymptomatic heterozygotic carriers; however, this prevalence is difficult to establish because of the absence of symptoms. Although
acute intermittent porphyria
is a multisystemic disease, its most common form of presentation is abdominal pain and neurological or mental symptoms, which can sometimes be due to precipitating factors such as reduced energy intake, smoking, alcohol, some drugs, and stress. Diagnosis can be made by testing urinary porphobilinogen levels, with subsequent measurement of enzyme activity and DNA testing. Treatment is based on prevention of porphyria attacks by avoiding precipitating factors and early administration of intravenous glucose or hemin therapy. We present the case of a patient diagnosed with
acute intermittent porphyria
based on study of chronic mild
alanine aminotransferase
(
ALT
) elevation.
...
PMID:[Acute intermittent porphyria and chronic transaminase elevation]. 1840 88
The objective of this study was to update the clinical issues of
acute intermittent porphyria
(
AIP
), as they have not been in focus for years, and to be aware of potentially associated disorders and social consequences. A total of 356 gene carriers of
AIP
from northern Sweden participated in this retrospective population-based study. Eight mutations were found with a predominance of W198X (89%). Clinical manifestations of
AIP
(manifest
AIP
) were identified in 42%, 65% were women. Women were more severely stricken by
AIP
attacks concerning number and duration, hospital admission and early onset. Men reporting most attacks were > 40 years of age. In addition to traditional symptoms during attacks, fatigue was commonly described. Chronic
AIP
symptoms and disability pension due to
AIP
were reported in about 20% of subjects. Precipitating factors were reported with evident sex differences. Half of the gene carriers who were on medications used drugs considered not safe (in 1999), mainly antihypertensive drugs. Smoking was associated with high
AIP
attack frequency. Elevated levels of
ALT
, bile acids, creatinine, U-ALA and U-PBG and decreased levels of creatinine clearance were associated with manifest
AIP
. The same was true for hypertension and myalgia in the legs. Hepatoma was strikingly overrepresented. The high prevalence of manifest
AIP
in this study could be explained by a mutation-dependent penetrance. Our results emphasize the importance of early diagnosis, counselling and treatment of attacks, screening and treatment of associated disorders.
...
PMID:Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study. 1940 33